Studies FOXP1-related developmental disorders using genetic, medical and thinking-skill tests
Studies people with FOXP1 gene changes, delayed development, speech difficulties and autism traits.
Plain-language title generated from the registry record
Registry title: FOXP1 Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing FOXP1-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.
Key facts
- Where
- New York, United StatesSee the site
Where in United States
- The Seaver Autism Center for Research and TreatmentNew York, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Icahn School of Medicine at Mount Sinai
- Trial code
- NCT03718923
- Record updated
- 6 October 2026
- Original description
FOXP1, also known as Forkhead-box Protein P1, is a transcription factor protein belonging to the FOX gene family. Disruptions in the FOXP1 gene cause a phenotype characterized by global developmental delay, speech deficits, mild dysmorphic features, and traits of autism spectrum disorder. This study seeks to characterize FOXP1-related neurodevelopmental disorders using a number of genetic, medical and neuropsychological measures.Read full original descriptionShow less
The Seaver Autism Center for Research and Treatment - Assessment Core
FOXP1, also known as Forkhead-box Protein P1, is a transcription factor protein belonging to the FOX gene family. Disruptions in the FOXP1 gene cause a phenotype characterized by global developmental delay, speech deficits, mild dysmorphic features, and traits of autism spectrum disorder. This study seeks to characterize FOXP1-related neurodevelopmental disorders using a number of genetic, medical and neuropsychological measures.
Inclusion: Eligible participants must have a documented variant affecting the FOXP1 gene that the research team determines to be likely or definitely pathogenic; Eligible participants must be at least 2 years of age.
Exclusion: none.